Treatment with Novartis’ Cosentyx (secukinumab) led to a significant reduction in disease activity compared to placebo in patients with non-radiographic axial…
Articles by Patricia Inacio PhD
Yisaipu, a biosimilar of Enbrel (etanercept), has been approved in China as a pre-filled syringe to treat ankylosing spondylitis, among…
Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira, has been approved by the U.S. Food and Drug Administration (FDA) for…
People with axial spondyloarthropathy are more prone to develop additional disorders — called “multimorbidity” — which is associated with…
People with ankylosing spondylitis and psoriatic arthritis both are prone to developing additional diseases (comorbidities). However, only in patients with…
Treatment with Simponi Aria (golimumab) for one year reduced the signs and symptoms of ankylosing spondylitis (AS) among adult…
Ankylosing spondylitis (AS) patients have a more than 50% increased risk of developing blood vessel clots, according to a population-based…
The risk for developing overall dementia and Alzheimer’s disease dementia is higher in patients with ankylosing spondylitis…
Ankylosing spondylitis (AS) patients younger than 40 and those treated with tumor necrosis factor inhibitors (TNFi) are at a…
Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people…